Post-Traumatic Stress Disorder (PTSD) Therapeutics Analysis, Clinical Trials and Developments

Press Release

Post-Traumatic stress disorder therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

Post-Traumatic Stress Disorder (PTSD) is a serious condition that occurs in people who have experienced or witnessed a life-threatening event, such as a natural disaster, serious accident, terrorist incident, sudden death of a loved one, war, rape, or other violent personal assault. The fear due to such incidents triggers many split-second changes in the body, which protect the body in adverse situations.

Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1238

Companies that are involved in developing therapeutics for PTSD have shown positive clinical results in the various phases of drug development. For instance, BNC210, a negative allosteric modulator of the A7 nicotinic acetylcholine receptor, is being developed by Bionomics Limited to treat patients with PTSD. The results from the phase II trial of BNC210 showed that BNC210 was safe and well tolerable in patients with PTSD.

Bionomics Limited, Pfizer Inc., India Globalization Capital Inc., Therapade Technologies LLC, Axim Biotechnologies Inc., H. Lundbeck A/S, and Otsuka Pharmaceutical Co. Ltd. are some of the major companies involved in the development of drug candidates for the treatment of PTSD.

PTSD Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Financial Sector

Comments are closed.